ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 1, 2016--
BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company
with a focus on pluripotent stem cell technologies, today announced that
an abstract evaluating Renevia® in ‘run-in’ patients with
HIV-associated facial lipoatrophy from the Renevia-02 trial will be
presented at the 14th annual International Federation for Adipose
Therapeutics and Science meeting (IFATS)
taking place from November 17-20, 2016, in San Diego, California. The
data will be reported in an oral presentation on Thursday, November 17.
The presentation will be given by Ramon Llull, MD, PhD, director of Stem
Europe Mallorca Center in Mallorca, Spain, and the principal
investigator of the Renevia trial. Dr. Llull will present data from
‘run-in’ patients in the pivotal trial. The data indicate that Renevia
was safely administered with no serious adverse events and 3-D imaging
suggests that volumetric improvements were sustained through a one-year
follow up. In addition, Dr. Llull will present the mechanistic rationale
and pre-clinical data on how Renevia may be able to generate new facial
tissue after transplantation.
Thursday, November 17
“Stromal Cell-Hydrogel Construct Possibly Generates Clinically
Relevant Neo-Tissue In Facial HIV-Lipoatrophy Phase 2 Pivotal
Multicenter Clinical Trial: Early Analysis On Testing Patient Sample”.
Ramon Llull, MD, PhD, Stem Europe Mallorca Center, Mallorca, Spain
Additionally, data from the laboratory of Derrick C. Wan, MD, Associate
Professor in the Department of Surgery at Stanford University Medical
Center, will be presented on pre-clinical data from the transplantation
of Renevia into a novel mouse model.
Thursday, November 17
“Three Dimensional Ultrasound For The Accurate Imaging And
Quantification Of Adipose And Synthetic Tissue Grafts”.
Charles P. Blackshear MD, MD, Department of Surgery, Stanford
University Medical Center
About Facial Lipoatrophy
Facial wasting or facial lipoatrophy is the loss of subcutaneous fat
from the face and is associated with medication for treatment of HIV
infection. The longer a person is on HIV medications, the greater the
likelihood of developing problems with facial wasting. Signs of
lipoatrophy include the loss of subcutaneous fat primarily in the
temporal region and cheeks and this tends to produce an emaciated
Renevia® is a medical device that was developed as a
replacement for whole adipose tissue in cell assisted lipotransfer (CAL)
procedures by recreating many aspects of the adipose tissue
extracellular matrix. Renevia’s hydrogel polymer network provides the
requisite amino acid sequences for adipose stromal vascular cell
attachment and supports proliferation, localization, and adipogenic
differentiation. Once implanted, Renevia provides a 3-dimensional matrix
with pliability comparable to that of native adipose tissue, restoring
texture in the short term while promoting soft tissue regeneration in
the long term.
An important attribute of the Renevia hydrogel is its high water
content, which is greater than 98 percent. As a result, the hydrogel is
highly permeable to oxygen, nutrients and other water-soluble
metabolites. Renevia mimics the extracellular matrix and the individual
components of the hydrogel can be cross-linked in situ, thereby allowing
the seeding of cells prior to injection in vivo without compromising
either the cells or the recipient tissues.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
Company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotimeinc.com.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161101005752/en/
Source: BioTime, Inc.
EVC Group, Inc.
Matt Haines, 917-733-9297
Gotham Communications, LLC
Bill Douglass, 646-504-0890